$COYA News

Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Coya Therapeutics Initiates Blinded Extension Phase Of Its ALSTARS Trial; Patients Who Complete The 24-Week Placebo-Controlled, Double-Blind Phase Enter The Blinded Extension Phase Of The Study

Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

Coya Therapeutics secures FDA fast track status for COYA 302

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Launches $30M At-The-Market Stock Offering Agreement With Leerink Partners

Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate

Coya Therapeutics Says FDA Grants Fast Track Designation For COYA 302, Proprietary Investigational Biologic Combination Therapy With Dual Mechanism Of Action, For ALS Treatment

NanoViricides to Participate at D. Boral Capital Global Conference in NYC

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

Coya Therapeutics shares are trading higher after the company announced a publication demonstrating that COYA 302 increased three biomarkers in ALS patients compared to controls.

Coya Therapeutics shares are trading higher after the company announced a publication demonstrating that COYA 302 increased three biomarkers in ALS patients compared to controls.

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS